Katabi Maha
SEC-identified person · CIK 1720685 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Vera Therapeutics, Inc. VERA | Director | filed 2021 - 2025 |
| Jade Biosciences, Inc. JBIO | Director | filed 2021 - 2024 |
| Rayzebio, Inc. RYZB | Director | filed 2023 - 2024 |
| Cincor Pharma, Inc. CINC | Officer | filed 2022 - 2023 |
| Bolt Biotherapeutics, Inc. BOLT | Officer | filed 2021 - 2021 |
| Inozyme Pharma, Inc. INZY | Officer | filed 2020 - 2020 |
| Akouos, Inc. AKUS | Officer | filed 2020 - 2020 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.